Downregulating USP9X can also reduce the expression levels of FLT3-ITD and its associated downstream signaling pathways, suggesting that USP9X represents a promising target for treating FLT3-ITD-positive AML patients. The gene discussed is USP9X; the disease is acute myeloid leukemia.